- Page 1 and 2:
An Introduction to Medicinal Chemis
- Page 3 and 4:
Preface This text is aimed at under
- Page 5 and 6:
Contents Classification of drugs xi
- Page 7 and 8:
Contents
- Page 9 and 10:
Contents xi 11.16.2 Structure
- Page 11 and 12:
Classification of drugs
- Page 13 and 14:
1 • Drugs and the medicinal chemi
- Page 15 and 16:
Whilst penicillin Drugs and the med
- Page 17:
Drugs
- Page 22 and 23:
10 The why and the wherefore Cytopl
- Page 25:
Where do drugs work? 13 Amphoterici
- Page 28:
16 Protein structure [ H O
- Page 31 and 32:
The tertiary structure of proteins
- Page 33 and 34:
The tertiary structure of proteins
- Page 36 and 37:
24 Protein structure H-Bond Peptide
- Page 38:
26 Protein structure again that ter
- Page 43 and 44:
Substrate binding
- Page 45 and 46:
Substrate binding at an active site
- Page 47:
Substrate binding
- Page 53 and 54:
R The catalytic role of enzymes Thy
- Page 55 and 56:
I NH 2 CHO (OH Condensation R< The
- Page 59 and 60:
Nerve Neurotransmitters
- Page 61 and 62:
Receptors
- Page 64 and 65:
52 Drug action at receptors Induced
- Page 66 and 67:
54 Drug action at receptors MESSENG
- Page 68:
56 Drug action at receptors RECEPTO
- Page 72 and 73:
60 Drug action at receptors left-ha
- Page 74 and 75:
62 Drug action
- Page 76 and 77:
64 Drug action
- Page 78 and 79:
66 Drug action at receptors D Neuro
- Page 81 and 82:
Structure of DNA 69 NH 2 NHo NHo Ad
- Page 83 and 84:
Structure
- Page 85 and 86:
Drugs acting
- Page 87:
Drugs acting on DNA 75 CH3—N: MEC
- Page 90 and 91:
78 Nucleic acids end AMINO «A/* Ba
- Page 93:
Summary 81
- Page 96 and 97:
84 Drug development
- Page 98 and 99:
86 Drug development | | Potential I
- Page 100 and 101:
88 Drug development bonding or not,
- Page 102 and 103:
90 Drug development 7.5.1 Variation
- Page 104 and 105:
92 Drug development covered
- Page 106 and 107:
94 Drug development avoiding patent
- Page 108 and 109:
96 Drug development ,OH OH GLIPINE
- Page 111:
Receptor theories
- Page 115 and 116:
Lead compounds
- Page 117 and 118:
A case study—oxamniquine
- Page 119 and 120:
A case study—oxamniquine
- Page 121 and 122: A case study—oxamniquine 109 CH 3
- Page 124 and 125: 112 Pharmacodynamics stream. Thirdl
- Page 127 and 128: Drug dose levels 115 can easily neg
- Page 129 and 130: Drug design for pharmacokinetic pro
- Page 131 and 132: Drug design
- Page 133 and 134: Drug design for pharmacokinetic pro
- Page 135 and 136: Drug design for pharmacokinetic pro
- Page 137 and 138: Drug design for pharmacokinetic pro
- Page 139: grown Neurotransmitters as drugs? 1
- Page 142 and 143: 130 Quantitative structure-activity
- Page 144 and 145: 132 Quantitative structure-activity
- Page 146 and 147: 134 Quantitative structure-activity
- Page 148 and 149: 136 Quantitative structure-activity
- Page 150 and 151: 138 Quantitative structure-activity
- Page 152 and 153: 140 Quantitative structure-activity
- Page 154 and 155: 142 Quantitative structure-activity
- Page 156 and 157: 144 Quantitative structure-activity
- Page 158 and 159: 146 Quantitative structure-activity
- Page 160 and 161: 148 Quantitative structure-activity
- Page 162 and 163: 150 Quantitative structure-activity
- Page 164: 152 Quantitative structure-activity
- Page 170 and 171: 158 Antibacterial agents
- Page 174 and 175: 162 Antibacterial agents MeO OMe Fi
- Page 176 and 177: 164 Antibacterial agents Fig. 10.15
- Page 178 and 179: 166 Antibacterial agents drug would
- Page 180 and 181: 168 Antibacterial agents -CH2- R—
- Page 182 and 183: 170 Antibacterial agents • Ineffe
- Page 185 and 186: Antibacterial agents which inhibit
- Page 187 and 188: Antibacterial agents which inhibit
- Page 189 and 190: Antibacterial agents which inhibit
- Page 191 and 192: groups Antibacterial agents which i
- Page 193: Antibacterial agents which inhibit
- Page 196 and 197: 184 Antibacterial agents Fig. 10.45
- Page 198 and 199: 186 Antibacterial agents = CH 3 C0
- Page 200 and 201: 188 Antibacterial agents Second- an
- Page 202 and 203: 190 Antibacterial agents Fig. 10.54
- Page 204 and 205: 192 Antibacterial agents
- Page 206 and 207: 194 Antibacterial agents [Normal Me
- Page 208 and 209: 196 Antibacterial agents L-Valine M
- Page 210 and 211: 198 Antibacterial agents L-LEU —
- Page 212 and 213: 200 Antibacterial agents which was
- Page 214 and 215: 202 Antibacterial agents o ,CO2H HN
- Page 216 and 217: 204 Antibacterial agents transferre
- Page 218 and 219: 206 The peripheral nervous system y
- Page 220 and 221: 208 The peripheral nervous system S
- Page 222 and 223:
210 The peripheral nervous system N
- Page 224 and 225:
212 The peripheral nervous system 1
- Page 227:
Agonists at the cholinergic recepto
- Page 231 and 232:
Water Design of acetylcholine analo
- Page 233:
Design
- Page 236 and 237:
224 The peripheral nervous system H
- Page 239 and 240:
A large variety Antagonists of the
- Page 241 and 242:
Antagonists
- Page 243 and 244:
Antagonists
- Page 245:
drug design Other cholinergic antag
- Page 249 and 250:
Anticholinesterases
- Page 251:
Anticholinesterase drugs 239 - Pyrr
- Page 254 and 255:
242 The peripheral nervous system M
- Page 256 and 257:
244 The peripheral nervous system F
- Page 259 and 260:
N—CH 3 MeO. R'O* R
- Page 261:
Morphine 249 12.2 Morphine 12.2.1 S
- Page 265:
Morphine 253 To conclude, the 6-hyd
- Page 269 and 270:
Development
- Page 271 and 272:
Development of morphine analogues 2
- Page 273 and 274:
Development
- Page 275 and 276:
Development
- Page 277 and 278:
Development of morphine analogues 2
- Page 279:
Development of morphine analogues 2
- Page 282 and 283:
270 The opium analgesics analgesic
- Page 284 and 285:
272 The opium analgesics acts as a
- Page 287:
Enkephalins
- Page 290 and 291:
278 The opium analgesics narcotic a
- Page 292:
280 The opium analgesics O II N —
- Page 297:
Searching
- Page 301 and 302:
Searching for a lead—AT-guanylhis
- Page 303:
Developing the lead—a chelation b
- Page 307:
Development of metiamide 295 meanin
- Page 311:
Development
- Page 315 and 316:
Further studies—cimetidine analog
- Page 317 and 318:
Further studies—cimetidine analog
- Page 319 and 320:
Further studies—cimetidine analog
- Page 321:
Famotidine and nizatidine 309 • R
- Page 325 and 326:
Appendix
- Page 327:
(vesicles) containing The action of
- Page 331 and 332:
The action of nerves 319 x Briv "-
- Page 333 and 334:
Secondary messengers
- Page 335:
Secondary messengers 323 the proces
- Page 338 and 339:
Appendix 4 • Bacteria and bacteri
- Page 340 and 341:
Glossary ADDICTION Addiction can be
- Page 342 and 343:
Further reading Albert,
- Page 345 and 346:
drug addiction 1, 3, 5, 127, 248, 2
- Page 347 and 348:
penillic acids 172 pentagastrin Ind